Sandoz Inc. Launches AmLactin® new Rapid Relief Restoring Cream with 15% lactic acid

PRINCETON, N.J., March 9, 2021 /PRNewswire/ -- Sandoz Inc. today announced the launch of AmLactin^® new Rapid Relief Restoring Cream. This new cream is the latest addition in the brand's moisturizing product line. AmLactin Rapid Relief Restoring Cream with 15% lactic acid is an everyday moisturizing cream that instantly transforms the skin's appearance. Lactic acid is clinically proven to boost the skin's natural renewal process through gentle exfoliation.

"We developed the Rapid Relief Restoring Cream to meet the needs of our customers with everyday dry skin. The new cream was formulated to be gentle on the skin as well as light, airy and virtually translucent," said Emily Harris, Marketing Director of Sandoz, Inc. "Consumers want products that actually do what they claim. Our innovation team designs the AmLactin skincare line with the right ingredients and the right concentration to deliver on the brand's promised results."

Developed to address flaky, ashy, dry skin, AmLactin Rapid Relief Restoring Cream contains 15% lactic acid plus three ceramides (1, 3, 6-II) providing 24-hour moisturization. It can be applied daily to large or small areas of the body such as arms, legs, trunk, elbows and hands, leaving visibly soft, youthful-looking skin.

"AmLactin is the unsung hero of drugstore moisturizers. With a 15% concentration of lactic acid, the Rapid Relief Restoring Cream helps my patients address everyday flaky, dry skin," said Dr. Kavita Mariwalla, board certified dermatologist of Mariwalla Dermatology. "I love how the Rapid Relief's rich, creamy formula is non-greasy."

About Lactic Acid
Lactic Acid, the key ingredient in AmLactin Rapid Relief Restoring Cream, has been studied in more than 50 clinical trials. The most significant skin improvements were achieved when the concentration of lactic acid was 10% or greater demonstrating that concentration matters.  

Skin benefits of Lactic Acid include:

• Boosts the skin's natural renewal process through gentle exfoliation
• Works to help retain skin brightness and luminosity
• Moisturizes to reduce the appearance of lines and wrinkles
• Improves skin texture and appearance for softer, smoother skin
• Is a powerful humectant that helps attract and retain moisture

Lactic Acid is a naturally occurring alpha-hydroxy acid (AHA) which can be derived from sources such as dairy and fruit. Lactic Acid is also a key component of the skin's Natural Moisturizing Factor and is considered a gentle acid used in many skin care products.

AmLactin Rapid Relief Cream is paraben-free, fragrance-free and non-greasy. It retails for $24.99 (12 oz. jar) and is available online at Amazon.com/AmLactin.

About AmLactin® Skin Care
AmLactin® is more than a moisturizer. The AmLactin® line of body lotions and creams contain between 12% and 15% lactic acid and gently exfoliate and deeply hydrate for softer, smoother the skin. The #1 dermatologist recommended moisturizer brand with lactic acid, AmLactin® has been relieving rough, dry skin for more than 20 years. 

For more information, visit the brand on Facebook and Instagram @AmLactin or at www.AmLactin.com.

Sunburn Alert: This product contains an alpha-hydroxy acid (AHA) that may increase your skin's sensitivity to sunburn. Be sun smart: use sunscreen, wear protective clothing, and limit sun exposure while using this product and for a week afterward.

Disclaimer 
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product's label. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sandoz
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world's leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2019 sales of USD 9.7 billion.

Sandoz on social media
LinkedIn: https://www.linkedin.com/company/sandoz/
Twitter: https://twitter.com/sandoz_global
Facebook: https://www.facebook.com/sandozglobal/
Instagram: https://www.instagram.com/sandozglobal

CEO Richard Saynor on LinkedIn: https://www.linkedin.com/in/richard-saynor/ 

SOURCE Sandoz

Related Links

http://www.AmLactin.com